Curie.Bio

MODERATE Tx General

Strategy Notes

Curie.Bio is a top-tier biotech accelerator with deep pharma networks and significant follow-on capital. The venture's AI-driven drug resistance prediction aligns well with their thesis, though the program is US-centric and the venture targets EU/France. Still, the strong scientific validation and founder background make it a worthwhile application if geography is flexible.

Key Materials

—

Your Notes

Status & Deadline

Status: HUMAN_REQUIRED
Deadline: —
Cycle: rolling
Amount: $380 million fund (for follow-on Series A investments)
Type: accelerator
URL: Apply

Update Status

Log Application

AI Pipeline

Research Programme Generate Draft

Status History

2026-07-31 OPEN → HUMAN_REQUIRED · The applicant must research Curie.Bio's current application process (likely via their website or direct contact), determine if geography is flexible, and prepare a pitch deck and business plan tailored to the accelerator's thesis on AI-driven drug resistance prediction.